SLC5A2 and Hyperkalemia: A study on the FIDELITY dataset demonstrated that finerenone provided comparable risk reductions in kidney and cardiovascular outcomes in patients on SGLT2 inhibitor treatment compared to those not, with preliminary signals suggesting a possible attenuation of hyperkalemia among concurrent SGLT2 inhibitor users [74].